Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Janssen reports positive data from hepatitis C drug trial

Janssen reports positive data from hepatitis C drug trial

24th April 2015

Janssen has announced new results from phase III clinical trials that further demonstrate the safety and efficacy of simeprevir in the treatment of hepatitis C virus (HCV).

Presented at the International Liver Congress 2015 of the European Association for the Study of the Liver, the data from the OPTIMIST-1 and OPTIMIST-2 trials highlights the clinical outcomes of simeprevir in an all-oral combination regimen in a wide range of patients with HCV infection.

It was shown that Janssen's drug delivered superior sustained virologic response at 12 weeks after treatment in 97 percent and 84 percent of patients respectively in the OPTIMIST-1 and OPTIMIST-2 studies.

These are the first clinical trial results that demonstrate the efficacy of simeprevir in combination with sofosbuvir in patients with genotype 1 chronic HCV infection, both with and without cirrhosis.

Gaston Picchio, hepatitis disease area leader at Janssen, said: "This data further demonstrates the role of simeprevir within the HCV treatment landscape, as it provides patients with an important therapeutic option."

The drug was approved in Europe last year and has also been recommended for NHS use in draft guidance from the National Institute for Health and Care Excellence.ADNFCR-8000103-ID-801784946-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.